Research Paper Volume 16, Issue 19 pp 12769—12780
Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling
Figure 4. Bezafibrate inhibited the expression of pro-inflammatory mediators TNF-α and IL-6 against CME. (A) Plasma levels of TNF-α; (B) Plasma levels of IL-6 (n=12, **, p<0.01 vs. control group; #, ##, p<0.05, 0.01 vs. CME group).